药物评价：普莫特拉格用于治疗肠易激综合征和胃食管反流病。

Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

作者信息

Evangelista Stefano

出版信息

Curr Opin Investig Drugs. 2007 May;8(5):416-22.

PMID:17520871

Abstract

Dynogen Pharmaceuticals Inc, under license from Mitsubishi Pharma Corp, is developing pumosetrag (MKC-733, DDP-733), an orally available gastroprokinetic agent and locally acting 5-HT3 partial agonist, for the potential treatment of irritable bowel syndrome (IBS) with constipation and nocturnal gastroesophageal reflux disease (GERD). In September 2005, Dynogen commenced a phase II proof-of-concept trial of pumosetrag in IBS with constipation; positive results were reported in February 2007 and a phase IIb trial was to start in the fourth quarter of 2007. In September 2006, the company had initiated a phase Ib trial in nocturnal GERD.

摘要

迪诺金制药公司（Dynogen Pharmaceuticals Inc）在获得三菱制药公司（Mitsubishi Pharma Corp）许可的情况下，正在研发普莫特拉（pumosetrag，MKC - 733，DDP - 733），这是一种口服可用的胃肠促动力剂和局部作用的5 - 羟色胺3（5 - HT3）部分激动剂，用于潜在治疗便秘型肠易激综合征（IBS）和夜间胃食管反流病（GERD）。2005年9月，迪诺金制药公司开始了普莫特拉治疗便秘型IBS的II期概念验证试验；2007年2月报告了阳性结果，并且IIb期试验计划于2007年第四季度启动。2006年9月，该公司启动了夜间GERD的Ib期试验。